Exact Sciences Q3 top-line up 87%; non-GAAP gross margin of 77%

• Exact Sciences (EXAS) Q3 results:
• Revenues: $408.4M (+86.7%); Screening revenue was $214.6M, -2% Y/Y.
• Precision Oncology revenue: $91.6M; COVID-19 testing revenue was $102.2M.
• GAAP Gross margin of 72%, non-GAAP gross margin was 77%.
• Net loss: ($219.9M); loss/share: ($1.46).
• non-GAAP EBITDA: $94.5M.
• Also, the company announced sale of of 8.6M common shares to fund cancer detection acquisitions.
• https://seekingalpha.com/news/3626401-exact-sciences-q3-top-line-up-87-non-gaap-gross-margin-of-77